{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:11:06Z","timestamp":1744114266783},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.7759\/cureus.63661","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T12:44:53Z","timestamp":1719924293000},"source":"Crossref","is-referenced-by-count":2,"title":["An Atypical Presentation of Fabry Disease in a Patient With Nephrotic Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Manasi","family":"Harale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun B","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayank","family":"Mundada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahsan A","family":"Faruqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivraj","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1051\/jbio\/2002196020183","article-title":"Fabry\u2019s disease (alpha-galactosidase-A deficiency): recent therapeutic innovations (Article in French)","volume":"196","author":"Germain DP","year":"2002","unstructured":"Germain DP. Fabry\u2019s disease (alpha-galactosidase-A deficiency): recent therapeutic innovations (Article in French). J Soc Biol. 2002, 196:183-90. 10.1051\/jbio\/2002196020183","journal-title":"J Soc Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/life12050623","article-title":"Fabry\u2019s disease: the utility of a multidisciplinary screening approach","volume":"12","author":"Monte MA","year":"2022","unstructured":"Monte MA, Veroux M, Rodolico MS, et al.. Fabry\u2019s disease: the utility of a multidisciplinary screening approach. Life (Basel). 2022, 12:623. 10.3390\/life12050623","journal-title":"Life (Basel)"},{"key":"ref3","article-title":"Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes","volume":"81","author":"Desnick RJ","year":"1973","unstructured":"Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med. 1973, 81:157-71.","journal-title":"J Lab Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng CM","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, et al.. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007, 30:184-92. 10.1007\/s10545-007-0521-2","journal-title":"J Inherit Metab Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz A","year":"2008","unstructured":"Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant. 2008, 23:1600-7. 10.1093\/ndt\/gfm848","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for Fabry disease","volume":"284","author":"Brady RO","year":"2000","unstructured":"Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA. 2000, 284:2771-5. 10.1001\/jama.284.21.2771","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton MH","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, et al.. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002, 81:122-38. 10.1097\/00005792-200203000-00003","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten M","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, et al.. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015, 10:36. 10.1186\/s13023-015-0253-6","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical pratice","volume":"360","author":"Michaud M","year":"2020","unstructured":"Michaud M, Mauhin W, Belmatoug N, et al.. When and how to diagnose Fabry disease in clinical pratice. Am J Med Sci. 2020, 360:641-9. 10.1016\/j.amjms.2020.07.011","journal-title":"Am J Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03499-w","article-title":"Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening","volume":"25","author":"Chen Z","year":"2024","unstructured":"Chen Z, Yin B, Jiao J, Ye T. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening. BMC Nephrol. 2024, 25:61. 10.1186\/s12882-024-03499-w","journal-title":"BMC Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann R","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA, et al.. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001, 285:2743-9. 10.1001\/jama.285.21.2743","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/265991-an-atypical-presentation-of-fabry-disease-in-a-patient-with-nephrotic-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T12:44:57Z","timestamp":1719924297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/265991-an-atypical-presentation-of-fabry-disease-in-a-patient-with-nephrotic-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.63661","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}